Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Investigational New Drugs
|
October 13, 2018
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
Clinton Yam, Rashmi K Murthy, Gaiane M Rauch, et al.
The Oncologist
|
August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer
Reva K Basho, Clinton Yam, Michael Gilcrease, et al.
Cancer Discovery
|
October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
Clinical Immunology (Orlando, Fla.)
|
January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer
R Connor Chick, G Travis Clifton, Diane F Hale, et al.
Clinical Breast Cancer
|
August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience
Rashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2022
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Sheheryar Kabraji, Jing Ni, Sarah Sammons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant
Jennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.
JAMA Oncology
|
November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer
|
May 18, 2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
Bora Lim, Rashmi K Murthy, Jangsoon Lee, et al.
Breast Cancer Research : BCR
|
November 5, 2025
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study
Maria Azhar, Felipe Soto, Amber Su, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Investigational New Drugs
|
October 13, 2018
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
Clinton Yam, Rashmi K Murthy, Gaiane M Rauch, et al.
The Oncologist
|
August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer
Reva K Basho, Clinton Yam, Michael Gilcrease, et al.
Cancer Discovery
|
October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
Clinical Immunology (Orlando, Fla.)
|
January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer
R Connor Chick, G Travis Clifton, Diane F Hale, et al.
Clinical Breast Cancer
|
August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience
Rashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2022
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Sheheryar Kabraji, Jing Ni, Sarah Sammons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant
Jennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.
JAMA Oncology
|
November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer
|
May 18, 2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
Bora Lim, Rashmi K Murthy, Jangsoon Lee, et al.
Breast Cancer Research : BCR
|
November 5, 2025
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study
Maria Azhar, Felipe Soto, Amber Su, et al.
Page
of 5